Spontaneous mutants of Candida albicans resistant to 5-fluorocytosine (5-FC) were isolated from a strain susceptible to 5-FC. These mutants were compared with 5-FC-resistant strains of C. albicans and Torulopsis glabrata isolated from patients treated with the drug and from untreated patients. Resistance to 5-FC was in all cases followed by a decreased susceptibility to 5-fluorouracil. Most strains were also more resistant to 5-fluorouridine and had a lowered incorporation of uridine. In one spontaneous mutant totally resistant to all three 5-fluoropyrimidines, the uridine monophosphate pyrophosphorylase activity was greatly decreased. The 5-FC-resistant strains were of two main phenotypic classes. Class one was unaffected by 5-FC at the highest concentration tested. The growth rate of strains belonging to the other class was markedly decreased by low concentrations of 5-FC, but these strains were still able to form colonies after 7 days of incubation on plates containing very high concentrations of the drug (2,000 ,g/ml). The frequency of spontaneous mutation of a susceptible strain to 5-FC resistance was fairly high. The number of mutants growing on media containing 5-FC was unchanged by concentrations ranging from 25 to 500 ,g/ml.
Spontaneous mutants of Candida albicans resistant to 5-fluorocytosine (5-FC) were isolated from a strain susceptible to 5-FC. These mutants were compared with 5-FC-resistant strains of C. albicans and Torulopsis glabrata isolated from patients treated with the drug and from untreated patients. Resistance to 5-FC was in all cases followed by a decreased susceptibility to 5-fluorouracil. Most strains were also more resistant to 5-fluorouridine and had a lowered incorporation of uridine. In one spontaneous mutant totally resistant to all three 5-fluoropyrimidines, the uridine monophosphate pyrophosphorylase activity was greatly decreased. The 5-FC-resistant strains were of two main phenotypic classes. Class one was unaffected by 5- FC at the highest concentration tested. The growth rate of strains belonging to the other class was markedly decreased by low concentrations of 5-FC, but these strains were still able to form colonies after 7 days of incubation on plates containing very high concentrations of the drug (2,000 ,g/ml). The frequency of spontaneous mutation of a susceptible strain to 5-FC resistance was fairly high. The number of mutants growing on media containing 5-FC was unchanged by concentrations ranging from 25 to 500 ,g/ml.
5-Fluorocytosine (5-FC) was oi iginally intended as a cytostatic agent (2) , but in animal experiments it proved to lack both cytostatic properties and the capacity to produce leucopenia (6) . However, in 1964 it was discovered (5) that the compound had a fungistatic effect in certain experimental fungus infections in mice. Experience has since shown that 5-FC should be regarded as one of the most important agents in the treatment of deep Candida infections (13) , especially of the urinary tract (13; J. Schonebeck, Proc. 5th Congr. ISHAM, Paris) and that it is also effective against infections due to Torulopsis glabrata (17) . It is relatively nontoxic (13, 14) , but clinical experience has shown that the development of resistance is common (15) . Emergence of microbial drug resistance was at first thought to be a problem mainly in the treatment of cryptococcosis, and only occasionally in the treatment of Candida infections (15) . More recent studies, however, have shown that resistance frequently develops during the treatment of candidiasis. Schonebeck and Ansehn (in preparation) found that 10 of 135 clinical isolates of C. albicans and 3 of 50 T. glabrata isolates showed a low degree of susceptibility to 5-FC. From 18 patients treated with the drug, four C. albicans and two T. glabrata strains were isolated which in vitro showed a greater degree of resistance to 5-FC. Resistant strains could be isolated more often from patients treated with low concentrations of the drug at the site of infection. This has been observed also by Shadomy (15) .
5-FC is converted to 5-fluorouracil (5-FU) by a cytosine deaminase in C. albicans and Saccharomyces cerevisiae before it is incorporated into ribonucleic acid (RNA) as 5-fluorouracil riboside (7, 8) . The 5-fluoropyrimidines, 5-FC, 5-FU, and 5-fluorouridine (5-FUI), have been shown to have antifungal properties against S. cerevisiae (7). Mutants of this fungus resistant to 5-fluoropyrimidines were recently described by Jund and Lacroute (7).
5-FC-resistant mutants of a susceptible strain of C. albicans were isolated by plating on different concentrations of 5-FC without the use of mutagens. The mechanism underlying the development of resistance has been studied, in part in these spontaneous mutants and in part in strains of C. albicans and T. glabrata isolated from treated and untreated patients.
MATERIALS AND METHODS
Microbial strains. The MCi/mmole ofuridine. The cells were grown to the same cell mass. Ice-cold trichloroacetic acid (S ml) was added to each culture and was allowed to precipitate for more than I hr. The precipitate was collected on a membrane filter (Millipore Corp.) and extensively washed, and the radioactivity was measured. Fig. 2 , the number of mutant clones was virtually the same in the range of 25 to 500,ug/ml. Below 25 ,g/ml, a larger number of resistant mutants were observed. In the plateau region (25 to 500 gng/fl), the number of mutant clones increased by a factor of 5 between 2 and 7 days of incubation.
With a concentration of 1,000 g/ml, a 20-fold increase was observed. Thus, it is apparent that about 80% of the mutants recovered after 7 days of incubation were affected by the drug, and were equally affected by concentrations ranging from 25 to 500 jg/ml. We assumed that after 7 days of incubation the total number of growing clones was very close to the total number of 5-FC-resistant mutants, since in separate experiments we wild-type strain H1200; the rest showed a moderately to markedly lowered capacity to utilize uridine present in the LB medium (Table 4) .
In no case could resistance to the 5-fluoropyrimidines be explained by an excretion of pyrimidines, since no mutant was able to feed the pyrB Escherichia coli strain La5.
Characterization of C. albicans and T. glabrata strains with decreased susceptibility to 5-FC isolated from treated and untreated patients. The C. albicans strains CA7 to CA19 and the T. glabrata strains TG1 to TG5 were characterized by testing a The respective mutant strain was grown over night in S ml of LB medium containing 3H-uridine. Each culture was cooled, and 5 ml of 10% icecold trichloroacetic acid was added and allowed to precipitate at 0 C for at least 1 hr. The precipitates were collected on membrane filters (Millipore Corp.) and washed five times with 0.1 M HCI; radioactivity was then measured. Strain H1200 was chosen as unit. their resistance to 5-fluoropyrimidines and their ability to incorporate 3H-uridine (Table 5) . CA7, CA8, and CA9 were susceptible strains taken from untreated patients, as were strains CA14 to CA16 and TG1 to TG3 which showed a decreased 5-FC susceptibility. TG4 and TG5 were isolated from the urine of a patient after 5-FC treatment. In two patients, the strains were isolated before (CA10 and CA17), during (CAll), and after (CA12, CA13, CA18, and CA19) treatment. All strains of T. glabrata were completely resistant to 5-FC and 5-FU and had an increased tolerance to 5-FUI (Table 5 ). Moreover, their incorporation of 3H-uridine was considerably lower than that of C. albicans H1200. The 5-FC-susceptible C. albicans strains were as susceptible to 5-FU and 5-FUI as the wild-type strain H1200. They also had a high 3H-uridine incorporation. Of eight C. albicans strains with decreased susceptibility to 5-FC, four were resistant to all three 5-fluoropyrimidines after 3 days of incubation. Two of them had a very low uridine incorporation (CAt5 and CA16). The other two (CA18 and CA19) were isolated from the same 5-FC-treated patient after an interval of 3 weeks. The resistance patterns and incorporation values suggest that the two strains were identical. The incorporation of uridine was fairly high but much lower than in the strain isolated before treatment (CA17). The other four strains (CAll to CA14) appeared susceptible to 5-FC after 3 days of incubation. After 7 days, however, they formed colonies on 5-FC concentrations of 250 to 1,000 pig/ml. Strain CAIO originated from the same patient as strains CAll Table 3 .
to CA13. Since the three strains (CAl to CA13) showed a similar increase in 5-FU and 5-FUI resistance, they are probably identical. Strain CA14 was highly resistant to 5-FUI after 3 days and also had a very low capacity to incorporate uridine, despite the fact that it appeared quite susceptible to 5-FC and 5-FU after this incubation period. None of the Candida strains isolated from patients was able to feed the pyrimidine-requiring E. coli strain La5. Growth in the presence of 5-FC of a clinical C. albicans strain and of resistant H1200 mutants. A common finding with clinical isolates of C. albicans, as well as with the H1200 mutants, was strains which were affected by low concentrations of the drug though they were still able to form colonies on very high concentrations if the time of incubation was prolonged. The growth in the presence of 5-FC of two such strains, one isolated from a patient (CA12) and one H1200 mutant (S23), was compared with that of strains H1200 and H12R3. The four strains were incubated in flasks containing YNB and different concentrations of 5-FC. As shown in Fig. 3 the growth of strain H12R3 was unaffected by 5-FC at the highest concentration tested, 1,000 ,ug/ml. The growth rate of the mutant S23 and of the clinical strain CA12 was markedly affected even by 1 ,ug of 5-FC per ml. However, growth, although reduced, was not completely inhibited at any concentration tested. The 5-FC-susceptible strain H1200 was able to grow and to produce two mass doublings in the presence of 1 to 50 ug of 5-FC per ml. The cell cultures were tested afterwards for their resistance to 5-FC on plates. No mutants were detected except in strain S23 cultivated in the presence of 1,000 ,ug of 5-FC/ml. These 5-FCresistant mutants were probably responsible for the increased growth rate observed after 90 hr in this flask (Fig. 3) .
DISCUSSION
The metabolism of pyrimidines and their incorporation into RNA has been studied in Salmonella and E. coli (for review, see 10). Cytosine can be deaminated to uracil, which is then converted to UMP. Uridine is either transformed to uracil or directly phosphorylated to UMP. The mechanisms of 5-FC resistance in S. cerevisiae have been elegantly worked out by Grenson (4) and by Jund and Lacroute (7) . They showed that resistance developed as a result of four types of mutation: (i) mutation in the cell membrane affecting a cytosine specific permease, (ii) mutation affecting cytosine deaminase production, (iii) mutation affecting UMP pyrophosphorylase activity, (iv) mutation giving rise to an increased de novo synthesis of pyrimidines (Fig. 4) . The first two types of mutation specifically affect 5-FC resistance; the latter two also affect resistance to 5-FU and, to a varying extent, resistance to 5-FUI.
The C. albicans strains most thoroughly investigated in our study were the wild strain H1200 The strains isolated from patients showed resistance patterns similar to those of the H1200 mutants. Of five T. glabrata strains isolated, one obtained from a patient treated with 5-FC was totally resistant to all 5-fluoropyrimidines. The other four were completely resistant to 5-FC and 5-FU and had increased resistance to 5-PUI compared with C. albicans H1200. Three of these four strains were isolated from nontreated patients. All five strains had a low incorporation of IHuridine.
The 5-FC-resistant C. albicans strains isolated from patients were of two main phenotypic classes. The size and number of phenotypic class one colonies was, after 3 days of incubation, not affected by any tested concentration of the 5-fluoropyrimidines (CA15, CA16, CA18, CAl9). Strains CA15 and CA16 had a low incorporation of 3H-uridine, but strains CA18 and CA19 were intermediate. This could be explained by one of the enzymes converting uridine to UMP being more specific in the latter strains, leading to utilization of uridine but not of its 5-fluoroanalogue. The strains in the other phenotypic class (CAl1 to CA14) were significantly affected by moderately low concentrations of 5-FC and apappeared to be as susceptible as strain H1200 to 5-FC and 5-FU after 3 days of incubation. After 7 days, however, these mutants formed colonies on 5-PC concentrations ranging between 250 and 1,000 ,g/ml. The H1200 mutants could also be divided into these two main phenotypic classes. Since the number of visible mutants increased by a factor of 5 (Fig. 2) between the second and seventh days of incubation, at least 80% of the total number of mutants selected in the concentration range of 25 to 500 ,ug/ml were of the latter type. Selecting mutants on 1 ,ug of 5-FC/ml considerably increased the number of mutants appearing to be susceptible after 2 days of incubation but still able to form colonies on high concentrations of 5-FC after 7 days of incubation ( Fig. 2 and Table 3 ). When two strains of this type, one clinical isolate (CA12) and one H1200 mutant (S23), were compared with strains H1200 and H12R3, it was shown that the growth of strains CA12 and S23 was considerably less on 1 ,ug of 5-FC/ml (Fig. 3) . The increase in cell mass on this 5-PC concentration was, for the first 30 hr of treatment, not greater than that of the 5-FCsusceptible strain H1200.
The distinction between these two phenotypic classes of 5-PC-resistant Candida mutants should be of clinical importance. When resistant mutants which form colonies of normal or nearly normal appearance after 2 days of incubation on 5-PCcontaining plates are isolated, it is our belief that the therapy should not be continued, for increased concentrations of the drug probably would be useless against infections with this class of resistant organisms. Infections caused by strains of the other class, although also forming normal or nearly normal colonies after 7 days of incubation on 5-FC-containing plates, may still be controlled by 5-FC at concentrations of 25 to 75 ,ug/ml. One such patient, a 70-year-old man with Candida in the urinary tract, was successfully treated with 5-PC. The infection was caused by a Candida strain which after 3 days of incubation formed visible but small colonies on 409 MAg of 5-PC per ml and nearly normal-sized colonies after 7 days of incubation on 1,638 ,ug of 5-FC per ml (Schdnebeck and Insehn, unpublished data).
The frequency of mutation to 5-FC resistance was found to be high. The possibility that 5-PC in itself might act as a mutagen is unlikely, since no radioactivity appeared in deoxyribonucleic acid after the susceptible H1200 strain was grown in the presence of '4C-labeled 5-FC (Normark and Schonebeck, unpublished data).
Since the agent possesses a low degree of toxicity, the occurrence of resistant strains is the main disadvantage of the drug. Our experiments clearly show that in cultures of H1200 the number of isolated mutants is constant over a wide range of 5-FC concentrations (25 to 500 ,g/ml). The number of resistant mutants occurring can therefore not be controlled by increasing concentrations of 5-FC above 25 ,ug/ml. Below this concentration, the number of isolated mutants was considerably higher. Thus, one may assume that the concentrations used in vivo for therapeutic purposes should not be lower than this.
